TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial
Brief Summary: An increasing number of patients survive critical illness and intensive care, but describe having impaired physical function several years after discharge as a consequence of extensive loss of muscle mass. Reasons for loss of muscle mass and physical function are multiple, but insufficient nutrition is likely to contribute.

This randomised trial will investigate the effect of an optimised nutrition therapy during intensive care, on short term clinical outcome and physical quality of life. We hypothesise, that early nutritional therapy, directed towards patient-specific goals for energy and protein requirements, will improve both short- and long-term outcomes.


Options:
A: Arm Label: Early Goal-Directed Nutrition; Type: EXPERIMENTAL; Interventions: Other: Early Goal-Directed Nutrition | Arm Label: ASPEN-guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: ASPEN-guidelines | Intervention Type: OTHER; Name: Early Goal-Directed Nutrition; Assigned to Arm(s): Early Goal-Directed Nutrition | Intervention Type: OTHER; Name: ASPEN-guidelines; Assigned to Arm(s): ASPEN-guidelines
B: Arm Label: SEN; Type: EXPERIMENTAL; Interventions: Drug: peptisorb | Arm Label: IMEN; Type: EXPERIMENTAL; Interventions: Drug: Stresson | Arm Label: SPN; Type: EXPERIMENTAL; Interventions: Drug: Parenteral nutrition | Arm Label: IMPN; Type: EXPERIMENTAL; Interventions: Drug: Omegaven, Dipeptiven | Intervention Type: DRUG; Name: peptisorb; Assigned to Arm(s): SEN | Intervention Type: DRUG; Name: Stresson; Assigned to Arm(s): IMEN | Intervention Type: DRUG; Name: Parenteral nutrition; Assigned to Arm(s): SPN | Intervention Type: DRUG; Name: Omegaven, Dipeptiven; Assigned to Arm(s): IMPN
C: Arm Label: SPN group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SPN | Arm Label: Control gr; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SPN; Assigned to Arm(s): SPN group
D: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Appalachian Cervical Cancer Prevention Project
Brief Summary: The purpose of this study is to determine whether a faith-placed lay health advisor intervention is effective in increasing use of Pap smears among middle-aged and older Appalachian women.


Options:
A: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay health advisor visits and newsletter | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lay health advisor visits and newsletter; Assigned to Arm(s): Early Intervention
B: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
C: Arm Label: Usual care / opportunistic screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Letter and informational sheet; Type: EXPERIMENTAL; Interventions: Other: Letter and informational sheet | Arm Label: Email; Type: EXPERIMENTAL; Interventions: Other: Email | Arm Label: Phone; Type: EXPERIMENTAL; Interventions: Other: Phone | Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Other: Multimodal | Intervention Type: OTHER; Name: Letter and informational sheet; Assigned to Arm(s): Letter and informational sheet | Intervention Type: OTHER; Name: Email; Assigned to Arm(s): Email | Intervention Type: OTHER; Name: Phone; Assigned to Arm(s): Phone | Intervention Type: OTHER; Name: Multimodal; Assigned to Arm(s): Multimodal
D: Arm Label: Usual Care mailing intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care mailing intervention | Arm Label: CIS support mailing intervention; Type: EXPERIMENTAL; Interventions: Other: CIS support mailing intervention | Intervention Type: OTHER; Name: Usual care mailing intervention; Assigned to Arm(s): Usual Care mailing intervention | Intervention Type: OTHER; Name: CIS support mailing intervention; Assigned to Arm(s): CIS support mailing intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD). Treatment with doses of GSK573719 dosed twice daily will also be included to further evaluate dosing frequency. Treatment with tiotropium (18 mcg) once daily via the Handihaler will be included as an active control. A placebo treatment will be included in order to evaluate absolute treatment effect of the different doses of GSK573719.


Options:
A: Arm Label: GSK573719, GW642444, GSK573719+GW642444, placebo; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719, GW642444, GSK573719+GW642444, placebo
B: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 125/25 mcg once-daily GSK573719/GW642444 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 125mcg once-daily GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo once-daily | Intervention Type: DRUG; Name: 125/25 mcg once-daily GSK573719/GW642444; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 125mcg once-daily GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Placebo once-daily; Assigned to Arm(s): Placebo
C: Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning
Brief Summary: This study will attempt to study the effect of memantine, on memory, and motor praxis/expressive language skills in children with autism.

The investigators will recruit children ages 6-12 years who are verbal and meet criteria for Autism Spectrum Disorder. The children will be assessed for memory function, expressive language output and motor skills/praxis. They will then be randomized to memantine or placebo for 6 months. The effects of this medication and its safety in this population will be studied over the 6 month period.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Extended-release guanfacine; Type: EXPERIMENTAL; Interventions: Drug: extended-release guanfacine | Arm Label: Inactive placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Inactive placebo | Intervention Type: DRUG; Name: extended-release guanfacine; Assigned to Arm(s): Extended-release guanfacine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning
Brief Summary: This study will attempt to study the effect of memantine, on memory, and motor praxis/expressive language skills in children with autism.

The investigators will recruit children ages 6-12 years who are verbal and meet criteria for Autism Spectrum Disorder. The children will be assessed for memory function, expressive language output and motor skills/praxis. They will then be randomized to memantine or placebo for 6 months. The effects of this medication and its safety in this population will be studied over the 6 month period.


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
Brief Summary: RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether stereotactic radiosurgery is more effective than whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery.

PURPOSE: This randomized phase III trial studies how well stereotactic radiosurgery works compared to whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery.


Options:
A: Arm Label: Arm I - WBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole-brain radiation therapy | Arm Label: Arm II - SRS; Type: EXPERIMENTAL; Interventions: Radiation: stereotactic radiosurgery | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): Arm II - SRS | Intervention Type: RADIATION; Name: whole-brain radiation therapy; Assigned to Arm(s): Arm I - WBRT
B: Arm Label: Arm I (SRS); Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Radiosurgery | Arm Label: Arm II (observation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: Stereotactic Radiosurgery; Assigned to Arm(s): Arm I (SRS)
C: Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): N/A
D: Arm Label: Surgery + Whole Brain Radiotherapy; Type: OTHER; Interventions: Procedure: Surgery + WBRT | Arm Label: RadioSurgery + Whole Brain Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiosurgery + WBRT | Intervention Type: PROCEDURE; Name: Surgery + WBRT; Assigned to Arm(s): Surgery + Whole Brain Radiotherapy | Intervention Type: RADIATION; Name: Radiosurgery + WBRT; Assigned to Arm(s): RadioSurgery + Whole Brain Radiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Novel Human Milk Fortifier in Preterm Infants
Brief Summary: The purpose of this study is to assess growth of preterm infants fed human milk supplemented with an experimental human milk fortifier.


Options:
A: Arm Label: New human milk fortifier; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human milk fortifier | Arm Label: Currently marketed fortifier; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Human milk fortifier | Arm Label: New human milk fortifier with new Ca source; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human milk fortifier | Intervention Type: DIETARY_SUPPLEMENT; Name: Human milk fortifier; Assigned to Arm(s): Currently marketed fortifier, New human milk fortifier, New human milk fortifier with new Ca source
B: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier
C: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation
D: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Novel Human Milk Fortifier in Preterm Infants
Brief Summary: The purpose of this study is to assess growth of preterm infants fed human milk supplemented with an experimental human milk fortifier.


Options:
A: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
B: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier
C: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk
D: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Brief Summary: The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.

Primary Objective:

To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic VCD cases, regardless of the severity, due to any of the four serotypes in children aged 2 to 14 years at the time of inclusion.

Secondary Objectives:

* To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.
* To describe the occurrence of serious adverse events (SAEs), including SAEs of special interest in all participants throughout the trial period.
* To describe the occurrence of hospitalized virologically-confirmed dengue (VCD) cases and the occurrence of severe (clinically-severe or as per World Health Organization (WHO) criteria) VCD cases, throughout the Surveillance Expansion period (SEP) and throughout the trial (from Day 0 to the end of the study).
* To describe the antibody response to each dengue serotype after Dose 2, after Dose 3, and 1 and 5 years after Dose 3.


Options:
A: Arm Label: CYD Dengue Vaccine Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: N/A
B: Arm Label: Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Sodium chloride (NaCl) 0.9% | Intervention Type: BIOLOGICAL; Name: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Assigned to Arm(s): Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Placebo: Sodium chloride (NaCl) 0.9%; Assigned to Arm(s): Control Group
C: Arm Label: Intervention clusters; Type: EXPERIMENTAL; Interventions: Biological: Biological (Male Wolbachia-infected Aedes aegypti) | Arm Label: Non-intervention clusters; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Biological (Male Wolbachia-infected Aedes aegypti); Assigned to Arm(s): Intervention clusters
D: Arm Label: CYD Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: (NaCl) 0.9% solution | Intervention Type: BIOLOGICAL; Name: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Assigned to Arm(s): CYD Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Placebo: (NaCl) 0.9% solution; Assigned to Arm(s): Placebo Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Technology-Assisted Case Management in Low Income Adults With Type 2 Diabetes
Brief Summary: The purpose of this study is to help low income patients achieve and maintain better self-management skills and improve blood sugar levels, using a 2-in-1 blood glucose and blood pressure monitoring system and nurse case management. Patients must be served at a Federally Qualified Health Center (FQHC) in coastal South Carolina.


Options:
A: Arm Label: Internet Intervention; Type: EXPERIMENTAL; Interventions: Other: Internet Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Internet Intervention; Assigned to Arm(s): Internet Intervention
B: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group based non-pharmacological rehabilitation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual non-pharmacological rehabilitation | Intervention Type: BEHAVIORAL; Name: Group based non-pharmacological rehabilitation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individual non-pharmacological rehabilitation; Assigned to Arm(s): 2
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management

Answer: D